Generic Orenitram Availability
Last updated on Oct 9, 2024.
Orenitram is a brand name of treprostinil, approved by the FDA in the following formulation(s):
ORENITRAM (treprostinil diolamine - tablet, extended release;oral)
-
Manufacturer: UNITED THERAP
Approval date: December 20, 2013
Strength(s): EQ 0.125MG BASE [RLD], EQ 0.25MG BASE [RLD], EQ 1MG BASE [RLD], EQ 2.5MG BASE [RLD] -
Manufacturer: UNITED THERAP
Approval date: October 7, 2016
Strength(s): EQ 5MG BASE [RLD]
Has a generic version of Orenitram been approved?
No. There is currently no therapeutically equivalent version of Orenitram available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orenitram. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,723,887
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
-
Patent 7,417,070
Patent expiration dates:
- July 30, 2026✓
- July 30, 2026
-
Patent 7,544,713
Patent expiration dates:
- July 14, 2024✓
- July 14, 2024
-
Compounds and methods for delivery of prostacyclin analogs
Patent 8,252,839
Issued: August 28, 2012
Inventor(s): Phares Ken & Mottola David
Assignee(s): United Therapeutics CorporationThis invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula.
Patent expiration dates:
- May 24, 2024✓
- May 24, 2024
-
Solid formulations of prostacyclin analogs
Patent 8,349,892
Issued: January 8, 2013
Inventor(s): Phares Kenneth R.
Assignee(s): United Therapeutics CorporationModerate moisture levels, such as greater than 3% but no greater than 7%, may be beneficial for solid formulations of certain prostacyclin analogs. Accordingly, a solid formulation containing a prostacyclin analog may be packaged inside a pharmaceutical packaging with such amount of a desiccant or a drying agent that after the storage the solid formulation may have a moderate level of moisture in it.
Patent expiration dates:
- January 22, 2031✓
- January 22, 2031
-
Compounds and methods for delivery of prostacyclin analogs
Patent 8,410,169
Issued: April 2, 2013
Inventor(s): Phares Ken & Mottola David
Assignee(s): United Therapeutics CorporationThis invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:
Patent expiration dates:
- February 13, 2030✓
- February 13, 2030
-
Process to prepare treprostinil, the active ingredient in Remodulin®
Patent 8,497,393
Issued: July 30, 2013
Inventor(s): Batra Hitesh & Tuladhar Sudersan M. & Penmasta Raju & Walsh David A.
Assignee(s): United Therapeutics CorporationThis present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Patent expiration dates:
- December 15, 2028✓✓
- December 15, 2028
-
Osmotic drug delivery system
Patent 8,747,897
Issued: June 10, 2014
Inventor(s): Kidane Argaw & Bhatt Padmanabh P.
Assignee(s): Supernus Pharmaceuticals, Inc.An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.
Patent expiration dates:
- August 11, 2031✓✓
- August 11, 2031✓✓
- August 11, 2031
-
Compounds and methods for delivery of prostacyclin analogs
Patent 9,050,311
Issued: June 9, 2015
Inventor(s): Phares Ken & Mottola David & Batra Hitesh
Assignee(s): United Therapeutics CorporationThis invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:
Patent expiration dates:
- May 24, 2024✓✓
- May 24, 2024
-
Compounds and methods for delivery of prostacyclin analogs
Patent 9,278,901
Issued: March 8, 2016
Inventor(s): Phares Ken & Mottola David & Jeffs Roger
Assignee(s): United Therapeutics CorporationThis invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Patent expiration dates:
- May 24, 2024✓
- May 24, 2024
-
Osmotic drug delivery system
Patent 9,393,203
Issued: July 19, 2016
Inventor(s): Kidane Argaw & Bhatt Padmanabh P
Assignee(s): Supernus Pharmaceuticals, Inc.An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Patent expiration dates:
- April 27, 2026✓✓
- April 27, 2026
-
Compounds and methods for delivery of prostacyclin analogs
Patent 9,422,223
Issued: August 23, 2016
Inventor(s): Phares Ken & Mottola David & Jeffs Roger
Assignee(s): United Therapeutics CorporationThis invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Patent expiration dates:
- May 24, 2024✓
- May 24, 2024
-
Process to prepare treprostinil, the active ingredient in remodulin®
Patent 9,593,066
Issued: March 14, 2017
Inventor(s): Batra Hitesh & Tuladhar Sudersan M. & Penmasta Raju & Walsh David A.
Assignee(s): United Therapeutics CorporationThis present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
-
Process to prepare treprostinil, the active ingredient in Remodulin®
Patent 9,604,901
Issued: March 28, 2017
Inventor(s): Batra Hitesh & Tuladhar Sudersan M. & Penmasta Raju & Walsh David A.
Assignee(s): United Therapeutics CorporationThis present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Patent expiration dates:
- December 15, 2028✓✓
- December 15, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 18, 2026 - INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
More about Orenitram (treprostinil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: agents for pulmonary hypertension
- Breastfeeding
Patient resources
- Orenitram drug information
- Orenitram Titration Kit Month 1
- Orenitram Titration Kit Month 2
- Orenitram Titration Kit Month 3
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.